Papers
1
Total Citations
2
H-Index
1
About
Baoquan Zhang is a leading clinical researcher in oncology, with a primary focus on hepatocellular carcinoma (HCC) and innovative perioperative treatment strategies. His work centers on combining immunotherapy and targeted therapy to improve outcomes for patients at high risk of recurrence after liver cancer surgery. In a landmark prospective, single-arm phase Ib study (2023), Zhang demonstrated the safety and preliminary efficacy of TQB2450 (PD-L1 blockade) combined with anlotinib as a perioperative treatment for high-risk HCC patients, achieving a notable objective response rate and manageable toxicity. This study, which has already garnered citations, represents a critical step toward integrating immune checkpoint inhibitors with anti-angiogenic agents in the neoadjuvant and adjuvant settings. Zhang’s contributions are shaping the future of multimodal therapy for liver cancer, offering new hope for reducing recurrence and extending survival. His research is widely recognized for its translational impact, bridging preclinical insights with clinical practice to address one of the most challenging malignancies.
Research Focus
Key Achievements
Top Papers
- 1